Evaluate the safety and efficacy, as determined by 90-day incidence of mortality or transplant, for intravenous (IV) DUR-928 (30 mg or 90 mg) in subjects with severe alcohol-associated hepatitis, also known as severe alcoholic hepatitis, (AH) with pre-treatment Maddrey Discriminant Function (MDF) score ≥ 32 and MELD scores 21-30

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

To evaluate the effect of EFX compared to placebo on fibrosisregression in subjects with compensated cirrhosis due to NASH at Week 36

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390